|
Gender (male)
|
4.03
|
1.85
|
0.045*
|
|
Age
|
0.826
|
1.01
|
0.36
|
|
TIL level
|
2.23
|
0.628
|
0.135
|
|
Number of positive regional lymph nodes
|
3.13
|
1.05
|
0.077
|
|
Characteristics of brain metastasis
|
|
Cerebellar metastases
|
6.43
|
2.19
|
0.011*
|
|
Midbrain/pons metastasis
|
3.24
|
2.09
|
0.072
|
|
Leptomeningeal disease
|
0.04
|
1.07
|
0.846
|
|
Other site metastasis
|
0.03
|
0.92
|
0.867
|
|
Size of largest brain metastases
|
0.816
|
1.01
|
0.367
|
|
Number of brain metastases
|
18.8
|
1.19
|
< 0.00005*
|
|
Presence of neurological symptoms
|
1.55
|
2.51
|
0.214
|
|
Required steroid for brain metastasis
|
1.55
|
2.51
|
0.214
|
|
Extracranial Metastasis
|
|
Presence of extracranial metastasis
|
2.29
|
1.49
|
0.13
|
|
Presence of liver metastasis
|
2.25
|
1.94
|
0.134
|
|
Presence of lung metastasis
|
0.527
|
1.30
|
0.468
|
|
Presence of bone metastasis
|
0.06
|
1.09
|
0.813
|
|
Presence of adrenal metastasis
|
5.39
|
4.50
|
0.02*
|
|
Therapy
|
|
Craniotomy
|
10.0
|
0.418
|
0.0015*
|
|
Stereotactic radiosurgery
|
7.72
|
0.434
|
0.0055*
|
|
Whole brain radiation therapy
|
16.2
|
3.85
|
0.0001*
|
|
Number of prior systemic therapies
|
0.613
|
1.09
|
0.434
|
|
Anti-CTLA4 antibody after BM
|
0.658
|
0.79
|
0.417
|
|
Anti-PD-1 antibody after BM
|
10.0
|
0.376
|
0.0016*
|
|
BRAF inhibitor after BM
|
0.05
|
1.07
|
0.82
|
